Saralasin

Saralasin is a synthetic angiotensin II antagonist and a non-peptide compound. It is used in medical research to understand the role of angiotensin II in the body. Saralasin is not used clinically due to its short half-life and the need for continuous infusion.

Pharmacology

Saralasin acts by blocking the effects of angiotensin II, a potent vasoconstrictor. It competes with angiotensin II for binding at the angiotensin II type 1 receptor (AT1), which is found in many tissues including vascular smooth muscle and the adrenal glands. By blocking the action of angiotensin II, saralasin causes vasodilation and reduces the secretion of aldosterone, a hormone that increases the reabsorption of sodium and water in the kidneys.

Clinical significance

Although saralasin is not used in clinical practice, it has been used in research to investigate the role of angiotensin II in conditions such as hypertension, heart failure, and kidney disease. Studies have shown that blocking the effects of angiotensin II can reduce blood pressure, improve heart function, and slow the progression of kidney disease.

Side effects

As with all medications, saralasin can cause side effects. The most common side effects are related to its vasodilatory effects and include flushing, headache, and hypotension. Rarely, saralasin can cause a rash or changes in liver function tests.

See also

• Angiotensin II receptor antagonist
• Angiotensin converting enzyme inhibitor

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  Saralasin